1 – 27 of 27
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
(
- Contribution to journal › Article
- 2010
-
Mark
Diagnostik och uppföljning av patienter med små M-komponenter. Med sikte på att undvika transformation till malign sjukdom.
(
- Contribution to journal › Scientific review
-
Mark
Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma? - response
(
- Contribution to journal › Letter
-
Mark
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
(
- Contribution to journal › Article
- 2009
-
Mark
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
(
- Contribution to journal › Article
-
Mark
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
(
- Contribution to journal › Published meeting abstract
-
Mark
Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma - Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
(
- Contribution to journal › Article
-
Mark
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
(
- Contribution to journal › Article
-
Mark
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
(
- Contribution to journal › Article
- 2006
-
Mark
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
(
- Contribution to journal › Article
-
Mark
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation
(
- Contribution to journal › Article
- 2005
-
Mark
Frustration över arbetsvillkoren hos svenska verksamhetschefer
(
- Contribution to journal › Article
-
Mark
Nordic Myeloma Study Group, the first 15 years: Scientific collaboration and improvement of patient care
(
- Contribution to journal › Scientific review
-
Mark
Management of patients with polycythaemia vera: results of a survey among Swedish haematologists
(
- Contribution to journal › Article
-
Mark
International Staging System for Multiple Myeloma.
(
- Contribution to journal › Article
- 2004
-
Mark
Physicians as clinical directors: working conditions, psychosocial resources and self-rated health.
(
- Contribution to journal › Article
-
Mark
High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation.
(
- Contribution to journal › Article
-
Mark
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
(
- Contribution to journal › Article
-
Mark
Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders
(
- Contribution to journal › Article
-
Mark
MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: Evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
(
- Contribution to journal › Article
- 2003
-
Mark
Patientspecifik kostnadsberäkning i sjukvården - bra bas för att värdera nya behandlingsmetoder
(
- Contribution to journal › Article
-
Mark
A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences.
(
- Contribution to journal › Article
-
Mark
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
(
- Contribution to journal › Article
- 2002
-
Mark
Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
(
- Contribution to journal › Article
- 1998
-
Mark
Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma
(
- Contribution to journal › Article